Hadassah

Hadassah Researchers Identify Source of Blood Clots in COVID-19 Patients

Tuesday, Jun 16 2020

Prof. Higazi and lab manager Suhair Abdee

Researchers around the world have been puzzled by a deadly COVID-19 complication that affects 30 percent of patients: the formation of large and small blood clots that create lethal blockages in the patient’s lungs, kidneys, heart, and brain. Prof. Abd Al-Roof Higazi, head of the Hadassah Medical Organization’s Department of Clinical Biochemistry and Division of Laboratories, has identified the mechanism that causes these clots.

Prof. Higazi and international colleagues published a seminal paper in the leading medical journal Blood about their discovery that alpha-defensin, a peptide (an amino-acid chain) speeds up the creation of blood clots and prevents their disintegration. This finding is crucial in understanding what is happening to COVID-19 patients because existing anticoagulant drugs don't impact alpha-defensin.

“We took blood samples from patients in Hadassah’s COVID-19 Outbreak department,” relates Prof. Higazi, “and found a high concentration of alpha-defensin.” The sicker the patient was, the researchers found, the higher the concentration of this peptide.

Prof. Higazi and lab manager Suhair Abdeen are working on a new way to dissolve the blood clots. They are testing colchicine, an oral medication used for gout and Familial Mediterranean fever. It has succeeded in reducing alpha-defensin levels and blood clots in mice, and they are awaiting approval to begin human trials.

Prof. Higazi believes if the drug reduces blood clots in COVID-19 patients, it will vastly reduce the numbers of patients needing respirators. “These patients have numerous blood clots in their lungs, preventing normative blood flow,” he explains.

In addition, he says, “We can give the drug to those with mild symptoms to prevent the development of blood clots.”

Read more.
Israel21C
The Jerusalem Post

Related Stories

alt_text

Thursday, Jul 2 2020

Leading a COVID-19-Free Hospital–a Vision Beyond the Virus at Hadassah

In the midst of the COVID-19 pandemic, Dr. Tamar Elram, director of Hadassah Hospital Mount Scopus, has been in the very unusual situation of running a large hospital...

READ MORE ›
alt_text

Wednesday, Jul 1 2020

Hadassah Colloquium Assesses Where We Are Headed With COVID-19

As frightening numbers of new COVID-19 cases plague Israel, Prof. Allon Moses, international infectious disease expert and immediate past director of the Hadassah Medical...

READ MORE ›
alt_text

Monday, Jun 29 2020

COVID-19 Nursing Care Leads to Collaborative Research by Hadassah Nurses

With a little distance from the first phase of the COVID-19 pandemic, Hadassah Medical Organization nurse educator and critical care specialist Julie Benbenishty...

READ MORE ›
alt_text

Monday, Jun 29 2020

First Commercial Antibody Serum Given at Hadassah to COVID-19 Patient

The Hadassah Medical Organization worked with an ultra-Orthodox communal organization to collect antibody-rich plasma from recovered COVID-19 patients...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More